BR0306706A - peptìdeo glp-1 estendido, métodos de estimulação do receptor de glp-1 em um indivìduo necessitando de normalização de glicose sanguìnea, de tratamento de um indivìduo profilaticamente para diabetes independente de insulina, de redução ou de manutenção do peso corporal, de tratamento da obesidade, e de tratamento de doenças, em um indivìduo necessitando do mesmo, uso de um composto de glp-1, processo de preparação de uma formulação farmacêutica, e, formulação farmacêutica - Google Patents
peptìdeo glp-1 estendido, métodos de estimulação do receptor de glp-1 em um indivìduo necessitando de normalização de glicose sanguìnea, de tratamento de um indivìduo profilaticamente para diabetes independente de insulina, de redução ou de manutenção do peso corporal, de tratamento da obesidade, e de tratamento de doenças, em um indivìduo necessitando do mesmo, uso de um composto de glp-1, processo de preparação de uma formulação farmacêutica, e, formulação farmacêuticaInfo
- Publication number
- BR0306706A BR0306706A BRPI0306706-8A BR0306706A BR0306706A BR 0306706 A BR0306706 A BR 0306706A BR 0306706 A BR0306706 A BR 0306706A BR 0306706 A BR0306706 A BR 0306706A
- Authority
- BR
- Brazil
- Prior art keywords
- glp
- treatment
- individual
- pharmaceutical formulation
- obesity
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title abstract 2
- 208000008589 Obesity Diseases 0.000 title abstract 2
- -1 and Substances 0.000 title abstract 2
- 239000008280 blood Substances 0.000 title abstract 2
- 210000004369 blood Anatomy 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000008103 glucose Substances 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- 230000000638 stimulation Effects 0.000 title abstract 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 title 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 title 1
- 102000004877 Insulin Human genes 0.000 title 1
- 108090001061 Insulin Proteins 0.000 title 1
- 230000037396 body weight Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 229940125396 insulin Drugs 0.000 title 1
- 238000012423 maintenance Methods 0.000 title 1
- 238000010606 normalization Methods 0.000 title 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 3
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 abstract 3
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 2
- 101001032756 Rattus norvegicus Granzyme-like protein 1 Proteins 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34647402P | 2002-01-08 | 2002-01-08 | |
| US40509702P | 2002-08-21 | 2002-08-21 | |
| PCT/US2003/000001 WO2003058203A2 (en) | 2002-01-08 | 2003-01-03 | Extended glucagon-like peptide-1 analogs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0306706A true BR0306706A (pt) | 2007-03-27 |
Family
ID=26994870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0306706-8A BR0306706A (pt) | 2002-01-08 | 2003-01-03 | peptìdeo glp-1 estendido, métodos de estimulação do receptor de glp-1 em um indivìduo necessitando de normalização de glicose sanguìnea, de tratamento de um indivìduo profilaticamente para diabetes independente de insulina, de redução ou de manutenção do peso corporal, de tratamento da obesidade, e de tratamento de doenças, em um indivìduo necessitando do mesmo, uso de um composto de glp-1, processo de preparação de uma formulação farmacêutica, e, formulação farmacêutica |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7482321B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1585959A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4282485B2 (cg-RX-API-DMAC7.html) |
| AR (1) | AR038102A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003200839B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR0306706A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2468700A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA04006679A (cg-RX-API-DMAC7.html) |
| PE (1) | PE20030820A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW200306202A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003058203A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7557183B2 (en) | 2003-03-19 | 2009-07-07 | Eli Lilly And Company | Polyethylene glycol linked GLP-1 compounds |
| EP2298337B1 (en) | 2003-12-09 | 2017-02-22 | Novo Nordisk A/S | Regulation of food preference using GLP-1 agonists |
| EP1709071A4 (en) * | 2004-01-08 | 2007-05-30 | Theratechnologies Inc | GLUCAGON LIKE PEPTIDE-1 ANALOGS WITH LONG PERFORMANCE |
| EP1758575A1 (en) | 2004-06-11 | 2007-03-07 | Novo Nordisk A/S | Counteracting drug-induced obesity using glp-1 agonists |
| WO2006023358A1 (en) * | 2004-08-18 | 2006-03-02 | Eli Lilly And Company | Selective vpac2 receptor peptide agonists |
| EP1845105A4 (en) | 2005-01-14 | 2009-02-18 | Wuxi Grandchamp Pharmaceutical | MODIFIED EXENDINES AND CORRESPONDING USES |
| KR20070120112A (ko) | 2005-03-18 | 2007-12-21 | 노보 노르디스크 에이/에스 | 연장형 ｇｌｐ-1 화합물 |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| CA2606894A1 (en) * | 2005-05-05 | 2007-02-15 | Cadila Healthcare Limited | Novel compounds as glp-i agonists |
| CN101166545B (zh) * | 2005-05-13 | 2011-06-15 | 伊莱利利公司 | Glp-1聚乙二醇化的化合物 |
| WO2007021498A1 (en) * | 2005-08-11 | 2007-02-22 | Eli Lilly And Company | Selective vpac2 receptor peptide agonists |
| ES2336575T3 (es) | 2005-09-22 | 2010-04-14 | Biocompatibles Uk Limited | Polipeptidos de fusion glp-1 (peptido-1 similar al glucagon) con resistencia aumentada a la peptidasa. |
| AU2006306236B2 (en) | 2005-10-26 | 2011-12-01 | Eli Lilly And Company | Selective VPAC2 receptor peptide agonists |
| HUE029798T2 (en) * | 2005-11-04 | 2017-03-28 | Glaxosmithkline Llc | Methods of administering hypoglycemic agents |
| US8338368B2 (en) | 2005-11-07 | 2012-12-25 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
| JP5096363B2 (ja) | 2005-12-16 | 2012-12-12 | ネクター セラピューティックス | Ｇｌｐ−１のポリマ複合体 |
| US20100048460A1 (en) * | 2006-02-28 | 2010-02-25 | Lianshan Zhang | Selective vpac2 receptor peptide agonists |
| WO2007113205A1 (en) * | 2006-04-03 | 2007-10-11 | Novo Nordisk A/S | Glp-1 peptide agonists |
| CA2648936C (en) | 2006-04-20 | 2013-07-09 | Amgen Inc. | Glp-1 compounds |
| DE602006009631D1 (de) | 2006-05-10 | 2009-11-19 | Biocompatibles Uk Ltd | GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung |
| PE20121528A1 (es) * | 2006-09-13 | 2012-12-12 | Smithkline Beecham Corp | Metodos para administrar agentes hipoglucemiantes de larga duracion |
| US8454971B2 (en) | 2007-02-15 | 2013-06-04 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| EP1972349A1 (en) * | 2007-03-21 | 2008-09-24 | Biocompatibles UK Limited | GLP-1 fusion peptides conjugated to polymer(s), their production and use |
| EP1975176A1 (en) * | 2007-03-27 | 2008-10-01 | Biocompatibles UK Limited | Novel glp-1 fusion peptides, their production and use |
| CA2693504A1 (en) | 2007-08-03 | 2009-02-12 | Eli Lilly And Company | Treatment for obesity |
| ES2558155T3 (es) | 2007-10-30 | 2016-02-02 | Indiana University Research And Technology Corporation | Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1 |
| TWI474835B (zh) | 2008-06-17 | 2015-03-01 | Univ Indiana Res & Tech Corp | 用於治療代謝病症及肥胖症之基於ｇｉｐ之混合激動劑 |
| KR20110039230A (ko) * | 2008-06-17 | 2011-04-15 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 생리학적 ｐＨ 완충액에서 강화된 용해도 및 안정성을 나타내는 글루카곤 유사체 |
| US8889618B2 (en) | 2008-11-07 | 2014-11-18 | The General Hospital Corporation | C-terminal fragments of glucagon-like peptide-1 (GLP-1) |
| ES2620610T3 (es) | 2008-12-10 | 2017-06-29 | Glaxosmithkline Llc | Composiciones farmacéuticas de albiglutide |
| RU2550696C2 (ru) | 2008-12-19 | 2015-05-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Основанные на амидах пролекарства пептидов глюкагонового надсемейства |
| EP2443146B1 (en) | 2009-06-16 | 2016-10-05 | Indiana University Research And Technology Corporation | Gip receptor-active glucagon compounds |
| IN2012DN06437A (cg-RX-API-DMAC7.html) | 2010-01-27 | 2015-10-09 | Univ Indiana Res & Tech Corp | |
| US8691763B2 (en) | 2010-05-04 | 2014-04-08 | Glaxosmithkline Llc | Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection |
| CN103079587B (zh) | 2010-05-13 | 2016-05-11 | 印第安纳大学研究及科技有限公司 | 呈现核激素受体活性的胰高血糖素超家族肽 |
| KR20130111923A (ko) | 2010-05-13 | 2013-10-11 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | G-단백결합 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드 |
| RU2580317C2 (ru) | 2010-06-24 | 2016-04-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов |
| WO2012054861A1 (en) | 2010-10-22 | 2012-04-26 | Nektar Therapeutics | Glp-1 polymer conjugates having a releasable linkage |
| WO2012054822A1 (en) | 2010-10-22 | 2012-04-26 | Nektar Therapeutics | Pharmacologically active polymer-glp-1 conjugates |
| US9040481B2 (en) | 2010-11-02 | 2015-05-26 | The General Hospital Corporation | Methods for treating steatotic disease |
| TWI538687B (zh) | 2010-11-24 | 2016-06-21 | 杜瑞克公司 | 生物可降解之藥物遞送組成物 |
| EA201390941A1 (ru) | 2010-12-22 | 2013-12-30 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Аналоги глюкагона, проявляющие активность на рецепторе gip |
| BR112013032717A2 (pt) | 2011-06-22 | 2017-01-24 | Univ Indiana Res & Tech Corp | coagonistas do receptor de glucagon/glp-1 |
| EA031230B1 (ru) | 2011-06-22 | 2018-12-28 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Агонисты глюкагонового рецептора/glp-1-рецептора |
| EP2729157B1 (en) * | 2011-07-06 | 2019-01-16 | The General Hospital Corporation | A pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) for use in treatment |
| CN102363633B (zh) * | 2011-11-16 | 2013-11-20 | 天津拓飞生物科技有限公司 | 胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用 |
| CN103957927B (zh) | 2011-11-17 | 2016-11-09 | 印第安纳大学研究及科技有限公司 | 呈现糖皮质激素受体活性的胰高血糖素超家族肽 |
| WO2013078396A2 (en) | 2011-11-23 | 2013-05-30 | Durect Corporation | Radiation-sterilized biodegradable drug delivery compositions |
| EP2864351B1 (en) | 2012-06-21 | 2016-08-10 | Indiana University Research and Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
| ES2646538T3 (es) * | 2013-06-20 | 2017-12-14 | Novo Nordisk A/S | Derivados de GLP-1 y sus usos |
| CA2932477C (en) | 2013-12-06 | 2023-10-10 | Baikang (Suzhou) Co., Ltd | Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs |
| US20160303242A1 (en) | 2013-12-09 | 2016-10-20 | Durect Corporation | Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same |
| ES2739289T3 (es) | 2014-11-27 | 2020-01-30 | Novo Nordisk As | Derivados de GLP-1 y sus usos |
| CN107108714B (zh) | 2014-12-17 | 2022-02-08 | 诺和诺德股份有限公司 | Glp-1衍生物及其用途 |
| HUE067499T2 (hu) | 2018-04-05 | 2024-10-28 | Sun Pharmaceutical Ind Ltd | Új GLP-1 analógok |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69737479T4 (de) * | 1996-08-30 | 2010-05-06 | Novo Nordisk A/S | Glp-1 derivate |
| ATE466027T1 (de) * | 1998-02-27 | 2010-05-15 | Novo Nordisk As | Abkömmlinge von glp-1 analogen |
| WO1999043707A1 (en) | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | N-terminally modified glp-1 derivatives |
| EP1306091A3 (en) | 1998-07-31 | 2003-05-21 | Novo Nordisk A/S | Stimulation of beta cell proliferation |
| DK1355942T3 (da) * | 2000-12-07 | 2008-11-17 | Lilly Co Eli | GLP-1-fusionsproteiner |
| EP2022505B1 (en) * | 2001-07-31 | 2011-12-14 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | GLP-1, exendin-4, peptide analogs and uses thereof |
| US7238663B2 (en) * | 2001-08-28 | 2007-07-03 | Eli Lilly And Company | Pre-mixes of GLP-1 and basal insulin |
| EP1448222A4 (en) * | 2001-10-19 | 2006-05-17 | Lilly Co Eli | BIPHASIC MIXTURES OF GLP-1 AND INSULIN |
-
2003
- 2003-01-03 CA CA002468700A patent/CA2468700A1/en not_active Abandoned
- 2003-01-03 WO PCT/US2003/000001 patent/WO2003058203A2/en not_active Ceased
- 2003-01-03 AR ARP030100014A patent/AR038102A1/es unknown
- 2003-01-03 MX MXPA04006679A patent/MXPA04006679A/es unknown
- 2003-01-03 TW TW092100093A patent/TW200306202A/zh unknown
- 2003-01-03 EP EP03700026A patent/EP1585959A4/en not_active Withdrawn
- 2003-01-03 AU AU2003200839A patent/AU2003200839B2/en not_active Ceased
- 2003-01-03 BR BRPI0306706-8A patent/BR0306706A/pt not_active IP Right Cessation
- 2003-01-03 US US10/499,111 patent/US7482321B2/en not_active Expired - Fee Related
- 2003-01-03 JP JP2003558463A patent/JP4282485B2/ja not_active Expired - Fee Related
- 2003-01-06 PE PE2003000021A patent/PE20030820A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003058203A2 (en) | 2003-07-17 |
| PE20030820A1 (es) | 2003-10-04 |
| AU2003200839B2 (en) | 2008-12-11 |
| EP1585959A2 (en) | 2005-10-19 |
| WO2003058203A3 (en) | 2007-02-01 |
| JP2005528337A (ja) | 2005-09-22 |
| US20060014241A1 (en) | 2006-01-19 |
| CA2468700A1 (en) | 2003-07-17 |
| TW200306202A (en) | 2003-11-16 |
| JP4282485B2 (ja) | 2009-06-24 |
| EP1585959A4 (en) | 2007-11-14 |
| MXPA04006679A (es) | 2004-11-10 |
| AU2003200839A1 (en) | 2003-07-24 |
| US7482321B2 (en) | 2009-01-27 |
| AR038102A1 (es) | 2004-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0306706A (pt) | peptìdeo glp-1 estendido, métodos de estimulação do receptor de glp-1 em um indivìduo necessitando de normalização de glicose sanguìnea, de tratamento de um indivìduo profilaticamente para diabetes independente de insulina, de redução ou de manutenção do peso corporal, de tratamento da obesidade, e de tratamento de doenças, em um indivìduo necessitando do mesmo, uso de um composto de glp-1, processo de preparação de uma formulação farmacêutica, e, formulação farmacêutica | |
| Monti et al. | Current and emerging treatments for the management of osteogenesis imperfecta | |
| BR0314372A (pt) | Compostos imidazol como inibidores do fator de crescimento tranformador (tgf) | |
| BRPI0210886B8 (pt) | composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal | |
| BRPI0206432A2 (pt) | métodos para administrar dois ou mais agentes terapêuticos ativos e para tratar diabetes melito ou sintomas associados com diabetes melito em um humano e sistema de liberação espaçada de medicamento | |
| BR0314619A (pt) | Análogos de ghrh | |
| US20220249605A1 (en) | Treatment of Mood and Anxiety Disorders | |
| UY27392A1 (es) | Derivados del ácido indan acetico y su uso como agentes farmacéuticos, intermediarios, y método de preparación | |
| Gonnelli et al. | The prevention of fragility fractures in diabetic patients | |
| IL208179A0 (en) | Nuckeic acud nolecules encoding human kremen 1 and human kremen 2 and diagnostic and pharmaceutical compositions based thereon | |
| BR0308154A (pt) | Emprego de epotilonas no tratamento de doenças cerebrais associadas com processos proliferativos | |
| BRPI0508865A (pt) | dispositivo de liberação de medicamento visìvel por raio x | |
| Servais et al. | FIREFISH part 2: efficacy and safety of risdiplam (RG7916) in infants with Type 1 spinal muscular atrophy (SMA) | |
| BRPI0418138A (pt) | medicamento compreendendo ptx3, sozinho ou em combinação com tsg-6, para tratar doenças degenerativas de cartilagem e ósseas e tratar infertilidade feminina | |
| BRPI0411169A (pt) | preparação injetável ou implantável e seu uso | |
| Ghosal et al. | Insulin glargine versus insulin degludec in patients failing on oral therapy in type 2 diabetes: a retrospective real world comparative data from India | |
| AU2005223694A1 (en) | Use of relaxin to increase arterial compliance | |
| BR112022027124A2 (pt) | Formulações para promover a hidratação e métodos de uso das mesmas | |
| Peña | The role of TRPA1 channels and Sigma-1 receptor in oxaliplatin-induced peripheral neuropathy | |
| Choi | Respiratory review of 2013: critical care medicine | |
| Kang et al. | A case of conversion disorder treated with Gaegyeolseogyeong-tang | |
| Galmarini et al. | Coronavirus, the immune system and vitamin D | |
| Zeni et al. | Local effects of low doses of pth 1-34 on experimental periodontitis | |
| Rodriguez Araujo et al. | Molecular pharmacology of Caenorhabditis elegans serotonin-gated chloride channel mod-1 as a novel drug target for anthelmintic therapy | |
| Prajith | A 28 year-old male had Levetriacetam induced drug eruptions-Skin desquamation and hyperpigmentation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A(S) 8A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011. |